Compare · APUS vs NVO
APUS vs NVO
Side-by-side comparison of Apimeds Pharmaceuticals US Inc. (APUS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APUS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 9818.7x APUS ($19.5M).
- Over the past year, APUS is down 21.6% and NVO is down 45.0% - APUS leads by 23.4 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 1 for APUS).
- NVO has more recent analyst coverage (25 ratings vs 0 for APUS).
- Company
- Apimeds Pharmaceuticals US Inc.
- Novo Nordisk A/S
- Price
- $1.27+1.60%
- $43.28+1.15%
- Market cap
- $19.5M
- $191.15B
- 1M return
- -11.19%
- -7.90%
- 1Y return
- -21.60%
- -45.02%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NYSE
- IPO
- 2025
- News (4w)
- 1
- 8
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest APUS
- SEC Form 10-Q filed by Apimeds Pharmaceuticals US Inc.
- SEC Form NT 10-Q filed by Apimeds Pharmaceuticals US Inc.
- Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program
- Apimeds Pharmaceuticals US Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 10-K filed by Apimeds Pharmaceuticals US Inc.
- Apimeds Pharmaceuticals US Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Other Events, Financial Statements and Exhibits
- Apimeds Pharmaceuticals US Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Apimeds Pharmaceuticals US Inc. filed SEC Form 8-K: Other Events
- SEC Form 425 filed by Apimeds Pharmaceuticals US Inc.
- Amendment: Apimeds Pharmaceuticals US Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care